Next Article in Journal
Increased Serum Levels of Phoenixin-14, Nesfatin-1 and Dopamine Are Associated with Positive Pregnancy Rate after Ovarian Stimulation
Previous Article in Journal
What Is the Role of Traction Test Radiographs in the Preoperative Planning of Adolescent Idiopathic Scoliosis?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 12
Issue 22
10.3390/jcm12226990
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

MMP9 Gene Polymorphism (rs3918242) Increases the Risk of Cardiovascular Disease in Type 2 Diabetes Patients

by
Monika Buraczynska
*,
Sylwia Wrzos
and
Wojciech Zaluska
Department of Nephrology, Medical University of Lublin, 20-093 Lublin, Poland
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2023, 12(22), 6990; https://doi.org/10.3390/jcm12226990
Submission received: 25 September 2023 / Revised: 20 October 2023 / Accepted: 4 November 2023 / Published: 8 November 2023
(This article belongs to the Section Clinical Laboratory Medicine)
Versions Notes

Abstract

:
Matrix metalloproteinase 9 (MMP-9) C(-1562)T gene polymorphism has been considered a risk factor for cardiovascular disease (CVD). Our study aimed to evaluate the association between this polymorphism and CVD in diabetes patients. The genotyping was performed in 740 patients with T2DM and 400 healthy subjects. A significant difference in the polymorphism distribution was revealed between patients and controls. The T allele and TT homozygote were associated with increased risk of diabetes (OR 1.88, p < 0.0001 and OR 3.77, p = 0.0002, respectively). The comparison between CVD+ and CVD− subgroups showed a much higher frequency of the T allele in patients with CVD (OR 2.87, 95% CI 2.14–3.85, p < 0.0001). Patients with the TT genotype had a higher prevalence of CVD (OR 3.19, 95% CI 1.55–6.56, p = 0.0015). The carrier genotypes (CT/TT) were correlated with HDL levels in both CVD+ and CVD− subgroups (p < 0.001 for both). In the logistic regression analysis, only C(-1562)T SNP was a significant predictor of CVD in diabetic patients (p < 0.001). In conclusion, our study suggests an association between MMP-9 C(-1562)T polymorphism and an increased risk of CVD in T2DM. If replicated in other studies, it could be considered a genetic marker for predicting risk of T2DM and its cardiovascular comorbidity.

1. Introduction

Type 2 diabetes mellitus (T2DM) is a chronic, heterogenous disorder of glucose homeostasis presenting with persistent hyperglycemia. It arises from insufficient insulin secretion and/or insulin resistance. T2DM constitutes close to 90% of diabetes cases and contributes to the burden on health care system [1]. This multifactorial condition is associated with high morbidity and mortality due to macrovascular and microvascular complications. The presence of cardiovascular disease (CVD) in patients with type 2 diabetes is a serious clinical problem. CVD is one of the most frequent causes of death among DM patients. It accounts for approximately 65 % of mortality in DM [2].
Matrix metalloproteinases (MMPs) are a large group of zinc-dependent endopeptidases that degrade various components of the extracellular matrix in both physiological and pathological processes [3,4]. They are synthesized and released in the form of pro-proteins that need to undergo a cleaving process to become biologically active. MMPs are engaged in the pathogenesis of atherosclerosis by promoting the migration, proliferation and differentiation of smooth muscle cells. They also induce and destabilize atherosclerotic plaques. The actions of metalloproteinases are controlled by the mechanisms of transcription and translation as well as by inhibitors [5,6]. The altered expression and dysregulated activity of MMPs have been observed in clinical conditions involving disorders of the musculoskeletal system, inflammatory processes and cardiovascular and cerebrovascular diseases [6,7,8,9].
Matrix metalloproteinase 9 (MMP9) (gelatinase B) has a proteolytic activity against proteins of connective tissue, mainly collagens, proteoglycans and elastin. It is highly expressed in atherosclerotic plaques and involved in plaque progression and rupture [10]. Elevated levels of MMP9 have been reported in coronary artery disease (CAD) and hypertension and are also related to cardiovascular events and mortality [11,12,13,14,15].
The human MMP9 gene is located in the chromosome region 20q11.2-q13.1 [16] and contains several single nucleotide polymorphisms. Genetic variants in the regulatory regions of the MMP9 gene are functionally important and modify levels of the protein [16,17,18]. The MMP9-1562 C/T, a single nucleotide polymorphism, is located in the promoter region of the MMP9 gene. It was reported to exert a functional allele-specific effect on gene transcription. A C-to-T substitution causes the loss of nuclear protein binding to the region and a rise in the transcriptional activity in macrophages. The CC genotype is associated with the decreased activity of promoter, whereas the T allele (CT and TT genotypes) induces higher transcriptional activity [16]. The -1562 C/T variant has been extensively studied and the T allele has been reported to be associated with elevated circulating MMP levels, cardiovascular disease and arterial stiffness [17,19,20,21]. MMP9 -1562 T allele carriers were predisposed to coronary atherosclerosis and had an increased severity of the disease [16]. This polymorphism was also reported to be associated with microvascular complications in diabetes [22]. We hypothesize that the minor allele of the MMP-9 -1562 C/T SNP is also associated with cardiovascular disease in subjects with T2DM.
Since the literature on the increased genetic susceptibility to CVD in diabetes patients is rather scarce, in this study we aimed to investigate an association between the -1562 C/T polymorphism in the MMP9 gene and the risk of cardiovascular disease in subjects with T2DM.

2. Materials and Methods

2.1. Study Subjects

All patients enrolled in this retrospective case–control study were recruited from University Hospital, Medical University of Lublin. The patient group included 740 unrelated subjects (392 males and 348 females) with type 2 diabetes of at least 10 years duration (mean age 57.2 ± 9.1 years). All patients were Caucasians of Polish origin. The same patient cohort and control groups were used as described in detail in our earlier study [23].
The diagnosis of type 2 diabetes was based on the American Diabetes Association criteria [24]. A complete physical examination of all subjects included plasma fasting glucose, glycated hemoglobin (HbA1c), full lipid profile, albumin-to-creatinine ratio (ACR), albumin excretion rate (AER) and body mass index (BMI) measurements.
The following exclusion criteria were applied: type 1 and other types of diabetes, acute or chronic inflammatory conditions, autoimmune diseases and history of malignancies.
Cardiovascular disease was diagnosed in 522 patients (70.5%). They had one or a combination of pathological phenotypes: congestive heart failure, left ventricular hypertrophy, angina pectoris, ischemic heart disease, myocardial infarction and ischemic cerebral stroke. The clinical presentation of CVD was verified by relevant biochemical tests, as well as the radiographic, echocardiographic and vascular diagnostic criteria.
The healthy control group of 400 individuals (mean age 57.5 ± 8.1 years) consisted of unrelated volunteers with no known history of diabetes and cardiovascular disease.
Participation in the study was voluntary and before being included all T2DM patients and healthy controls provided a written informed consent, in accordance with principles of the Declaration of Helsinki (version 2013). The ethical approval of the detailed research protocol for the study was provided by the Bioethics Committee of the Medical University of Lublin (KE-0254/26/01/2023).

2.2. Determination of MMP9 rs3918242 (-1562 C/T) Genotype

After collecting 5 mL of peripheral venous blood from all enrolled individuals, genomic DNA was extracted from leukocytes via the standard procedure. The DNA concentration and its purity were determined using a Nano Drop 2000 (Thermo Scientific, Waltham, MA, USA). DNA samples were stored at −70 °C before use. The rs3918242 variant in the MMP9 gene was detected with amplification of the 435 bp DNA target via a polymerase chain reaction (PCR) assay. The following sequence-specific primers were used for DNA amplification: the sense primer 5′-GCCTGGCACATAGTAGGCCC-3′ and antisense primer 5′-CTTCCTAGCCAGCCGGCATC-3′, as reported earlier [25]. The conditions for the PCR reactions were slightly modified, starting with an initial denaturation step at 95 °C for 5 min, followed by 35 cycles of denaturation at 95 °C for 30 s, annealing at 65 °C for 1 min and extension at 72 °C for 1 min. The length of the PCR product was 435 bp. The polymorphism was detected by digesting amplicons with Sph I restriction endonuclease (Thermo Scientific) and separating DNA fragments on a 2% agarose gel. The C allele showed as an undigested 435 bp fragment, whereas the polymorphic variant (T allele) produced two fragments of 247 bp and 188 bp. The case/control status of the DNA samples was blinded for genotyping. The validation of genotypes was performed by repeating PCR amplification in 20% of random samples. In addition, 20 samples for each genotype were re-analyzed via sequencing using the CEQ 8000 Genetic Analysis System (Beckman Coulter, England) for the correctness of genotype reading in agarose gel. A 100% concordance was achieved between the genotyping assays.

2.3. Statistical Analysis

Statistical analysis of the results was conducted using SPSS software (version 19) (SPSS, Inc., Chicago, IL, USA). In descriptive statistics for the differences in the baseline parameters between the case and control groups, the normally distributed quantitative data are shown as means ± SD. Categorical variables are represented as numbers and percentages. The frequencies of alleles and genotypes were obtained by direct counting. The potential deviation in genotype distribution from the Hardy–Weinberg equilibrium (HWE) was assessed with the chi-squared test. The genotype/allele frequencies were compared between groups (T2DM patients and controls) and subgroups (CVD+ and CVD− patients) using a chi-squared test of independence with 2 × 2 contingency and z statistics. For comparison of continuous and categorical variables between groups, we used the t test and Pearson’s Χ2 test of independence. The odds ratios (OR) with corresponding 95% confidence intervals (CI) were reported for associations. ORs were adjusted for age, gender, lipid parameters and T2DM duration. Unconditional logistic regression analysis was carried out for confirming the rs3918242 association with disease and interaction with other risk factors. A two-tailed type I error rate of 5% was regarded as statistically significant.

3. Results

3.1. Subject Characteristics

The genotype of the rs3918242 SNP in the MMP9 gene was determined in a total of 740 patients with T2DM and 400 healthy control subjects. The success rate for genotyping was 100%. The minor allele frequency was similar to that reported in another Polish study [26]. The comparison of the demographic features and clinical and laboratory parameters of diabetic patients and controls is presented in Table 1. In a group of 740 patients with T2DM, 522 (70.5%) had cardiovascular disease. All parameters were compared between this subgroup (CVD+) and 218 T2DM patients without CVD (CVD−). The gender distribution was similar in patients with CVD and without CVD (p = 0.082). On the other hand, patients with CVD were older than those without it (p < 0.001). A statistically significant difference was also observed in the age at diagnosis of T2DM (p = 0.007) and disease duration (p < 0.001). As expected, there was a significant difference in the levels of total cholesterol, HDL cholesterol and triglyceride between the CVD+ and CVD− subgroups. Significant differences between T2DM patients and healthy controls were seen in age, total cholesterol level and BMI (p < 0.001 for all variables).

3.2. Genotyping Analysis

The genotyping results of the rs3918242 SNP in the MMP-9 gene in patients and controls are presented in Table 2. The genotype frequencies in the T2DM and control groups were as predicted by the Hardy–Weinberg equilibrium (p = 0.259 for patients and p = 0.580 for controls). In the comparison of the polymorphism distribution in the T2DM and control groups, we observed a statistically significant difference. The T allele and TT homozygote were associated with an increased risk of T2DM (OR 1.88, 95% CI 1.51–2.34, p < 0.0001 and OR 3.77, 95%CI 1.88–7.56, p = 0.0002, respectively).

3.3. Association between -1562 C/T SNP and the Risk of Cardiovascular Disease

All T2DM patients were stratified into CVD+ (n = 522) and CVD− (n = 218) subgroups for further comparisons (Table 2). The frequencies of the T allele and TT genotype were significantly increased in T2DM CVD+ patients compared with those without CVD. The odds ratio for the T allele was 2.87, 95% CI 2.14–3.85 (p < 0.0001) and for the TT genotype it was 3.19, 95% CI 1.55–6.56 (p = 0.0015). This indicates that the risk of developing CVD in the carriers of the T allele was three-fold higher than in non-carriers. As presented in Table 3, there was no significant association observed between the MMP-9 rs3918242 polymorphism and CVD risk using the recessive genetic model (OR 1.82, 95% CI 0.89–3.69, p = 0.0976). Overall, the results show statistically significant association in two genetic models, codominant (Table 2) and dominant (Table 3), with OR 2.87, 95% CI 2.14–3.85, p < 0.0001 and OR 4.26, 95%CI 3.0–6.06, p < 0.0001, respectively).
Table 4 shows the CVD-associated parameters according to the carrier and non-carrier genotypes of MMP-9 rs3918242 polymorphism. The carrier genotype (CT/TT) was correlated with the HDL level in both the CVD+ and CVD− subgroups (p < 0.001 and p = 0.005, respectively). The other parameters did not show any significant association with genotype.
Multiple logistic regression analysis was carried out to confirm the independent risk factors for CVD in diabetes patients (Table 5). It was found that only MMP-9 rs3918242 polymorphism and diabetic retinopathy were significant risk predictors for CVD development in T2DM patients (p < 0.001 and 0.028, respectively).

4. Discussion

The presence of cardiovascular disease in type 2 diabetes patients is a serious clinical problem [27]. Matrix metalloproteinase MMP-9 is of particular importance in the development of CVD as it is expressed in numerous cardiovascular cell types, mainly in cardiomyocytes, cardiac fibroblasts, vascular endothelial cells and inflammatory cells [6]. Several studies have documented MMP-9’s contribution to CVD in individuals with diabetes.
In this study, we assessed the association between the -1562 C/T polymorphism (rs3918242) in the MMP9 gene and the susceptibility to cardiovascular disease in T2DM patients. This SNP was selected based on earlier association studies in cardiovascular diseases. The previous reports demonstrated that this polymorphism is associated with diabetes. Along with a direct impact on type 2 diabetes, studies have also reported links to metabolic syndrome and complications associated with T2DM. It has possible effects on diabetic nephropathy, retinopathy, diabetic foot and macroangiopathy [22,28,29]. In our study, the minor T allele carriership was associated with type 2 diabetes. A total of 49% of individuals were T allele carriers in the T2DM patient group compared with 31.5% in the control group (p < 0.0001). The risk of T2DM for the T allele carriers was over two-fold higher than for non-carriers.
For the analysis of an association between the -1562 C/T SNP and cardiovascular disease, the distribution of the polymorphism was compared in the CVD+ and CVD− subgroups of T2DM patients. A strong association between the T allele and TT homozygous genotype and the occurrence of cardiovascular disease was observed in this analysis in two genetic models (co-dominant and dominant). The increased frequency of T allele carriers in the T2DM CVD+ subgroup supports the role of the T allele as a genetic susceptibility factor for CVD. Earlier, Buraczynska et al. studied the association of the MMP-9 -1562 C/T gene polymorphism with the risk of stroke in 322 Polish patients (52% of patients had type 2 diabetes). Their findings suggested that -1562C/T genotypes are significantly associated with the ischemic stroke risk in patients with and without diabetes. They concluded that although the observed effect on susceptibility to stroke is modest, it might be enhanced by interaction with other genetic factors [30]. The association of the MMP-9 -1562 C/T SNP with CVD was also found in another Polish study of 110 subjects with coronary atherosclerosis. The results indicated that C to T transition is associated with premature ischemic heart disease in the studied cohort [31].
The same polymorphism was investigated in relation to cardiovascular diseases in other European studies. Watson et al. evaluated the association of the rs3918242 MMP-9 gene polymorphism (-1562 C/T) with hypertension, myocardial infarction and ventricular dysfunction in Irish patients with diabetes. In a cohort of 498 T2DM patients, they observed a two-fold higher risk of myocardial infarction and a lower ejection fraction (OR2.56, p = 0.026) in the carriers of the minor T allele of this polymorphism [32]. These data might be important in relation to the burden of heart failure in diabetic patients and emphasize the potential of MMP-9 polymorphism as a biomarker [32]. In a cohort of 1000 Norwegian patients with angiographically verified stable CAD and metabolic syndrome, the authors analyzed the effect of the -1562 C/T polymorphism on the clinical events after a 2-year follow-up. They observed a five-fold increase in the risk of clinical events in the T allele carriers of the -1562 C/T polymorphism. This effect was probably mediated through elevated MMP-9 levels and altered regulation of MMP-9 [33]. Blankenberg et al. performed a prospective study of 1127 patients with CAD, analyzing MMP-9 levels as a novel predictor of CV mortality and the genotypes of two MMP-9 gene polymorphisms: -1562 C/T and R279Q. The T allele of the -1562 C/T SNP was associated with increased MMP-9 levels. The R279Q polymorphism had no direct effect on MMP-9 concentration but was associated with CV events in patients with stable angina [17]. Boshev et al. studied the rs3918242 polymorphism in a younger population with CAD and concluded that this polymorphism could be used for clinical risk assessment for the development of CAD [34].
Reports from other populations also indicate that the MMP-9 gene -1562 C/T polymorphism is associated with the risk of cardiovascular disease. In a study of 261 Chinese patients with coronary artery disease, the authors investigated the correlation of the -1562 C/T polymorphism and the susceptibility to CAD. The TT and CT genotypes of this polymorphism were strongly associated with a raised risk of coronary artery disease [35]. A study of 236 Mexican patients with a history of myocardial infarction revealed an association between a functional -1562 C/T promoter region polymorphism and the risk of developing MI. The risk for the carriers of the T allele was almost three-fold higher than for patients with the CC genotype. According to the authors, the results of their study support the role of this polymorphism as a genetic marker for susceptibility to MI [21]. Similarly, the -1562 C/T polymorphism was found to be strongly associated with MI in another study involving 206 patients with acute myocardial infarction [20]. Some studies have reported contradictory results. In a study of 1287 individuals with myocardial infarction (854 patients) and stroke (367 patients), the MMP-9 SNPs were not significantly associated with MI or stroke [36]. In a study by Mahmoodi et al. on 100 patients with coronary artery disease, -1562 C/T polymorphism in the MMP-9 gene was not associated with CAD [37]. In an Indian study of young patients with ST-segment elevation MI, no relationship was found between -1562 C/T polymorphism and the disease [38]. These discrepancies between studies might be related to the different genetic backgrounds in the studied populations or to variations in the study design or selection criteria for the patients and controls.
The exact mechanism of the effect of the MMP-9 -1562 C/T polymorphism in the promoter region of the gene on the susceptibility to cardiovascular disease is unknown. It was found that the transcriptional activity of the T allele was significantly increased compared with the activity of the wild-type C allele [19,39]. Thus, increased expression levels of the MMP-9 gene may have an atherogenic effect. It was reported from autopsy studies that the aortic and coronary arteries of diabetic patients showed higher expression of MMP-9 compared with patients without diabetes. The MMP-9 levels were correlated with HbA1c and apoptosis [40]. In diabetes patients, chronic low-grade inflammation can cause variations in extracellular matrix turnover and adverse changes in myocardial tissues [41].
Our study has certain limitations. Although we applied strict selection criteria to define our patient and control groups, there was a potential selection bias due to the design of the study being retrospective. Patients were enrolled regardless of the time of CVD diagnosis. It is possible that some of the T2DM patients classified as CVD− could have undetected subclinical atherosclerosis that could affect the results. Furthermore, our study was restricted to one SNP in the MMP-9 gene, so the effect of other polymorphisms at this locus on the development of CVD cannot be excluded. The other limitation is that the functional consequences of the rs3918242 polymorphism were not investigated in our study.
In conclusion, the results of our study suggest a strong association between the MMP-9 -1562 C/T (rs3918242) gene polymorphism and an increased risk of cardiovascular disease in type 2 diabetes patients. The polymorphism can be considered as a potential marker for predicting the risk of type 2 diabetes and cardiovascular comorbidities/complications in diabetic patients. It is novel, clinically relevant information and, if replicated in a larger cohort of T2DM patients, could play an important role in personalized medicine.

Author Contributions

M.B. designed and supervised the study, performed research, interpreted the results and wrote the manuscript. S.W. recruited patients, collected data, contributed to statistical analysis and participated in research. W.Z. interpreted the results from a clinical perspective and contributed to editing the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Bioethics Committee of Medical University of Lublin.

Informed Consent Statement

Informed consent was obtained from all individuals involved in the study.

Data Availability Statement

The data supporting the findings of this study are available on request from the corresponding author.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Cho, N.H.; Shaw, J.E.; Karuranga, S.; Huang, Y.; da Rocha Fernandes, J.D.; Ohlrogge, A.W.; Malanda, B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Clin. Pract. 2018, 138, 271–281. [Google Scholar] [CrossRef] [PubMed]
  2. Visaria, J.; Iyer, N.N.; Raval, A.; Kong, S.; Hobbs, T.; Bouchard, J.; Kern, D.M.; Willey, V. Incidence and prevalence of microvascular and macrovascular diseases and all cause mortality in type 2 diabetes mellitus. A 10 year study in a US commercially insured and Medicare Advantage population. Clin. Ther. 2019, 41, 1522–1536. [Google Scholar] [CrossRef] [PubMed]
  3. Visse, R.; Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function and biochemistry. Circ. Res. 2003, 92, 827–839. [Google Scholar] [CrossRef]
  4. Cui, N.; Hu, M.; Khalil, R.A. Biochemical and biological attributes of matrix metalloproteinases. Prog. Mol. Biol. Transl. Sci. 2017, 147, 1–73. [Google Scholar] [CrossRef] [PubMed]
  5. Gallis, Z.S.; Khatri, J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ. Res. 2002, 90, 251–262. [Google Scholar] [CrossRef]
  6. Simões, G.; Pereira, T.; Caseiro, A. Matrix metaloproteinases in vascular pathology. Microvasc. Res. 2022, 143, 104398. [Google Scholar] [CrossRef] [PubMed]
  7. Siefert, S.A.; Sarkar, R. Matrix metalloproteinases in vascular physiology and disease. Vascular 2012, 20, 210–216. [Google Scholar] [CrossRef]
  8. Chen, Q.; Jin, M.; Yang, F.; Zhu, J.; Xiao, Q.; Zhang, L. Matrix metalloproteinases: Inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediat. Inflamm. 2013, 2013, 928315. [Google Scholar] [CrossRef] [PubMed]
  9. Mittal, R.; Patel, A.P.; Debs, L.H.; Nguyen, D.; Patel, K.; Grati, M.; Mittal, J.; Yan, D.; Chapagain, P.; Liu, X.Z. Intricate functions of matrix metalloproteinases in physiological and pathological conditions. J. Cell. Physiol. 2016, 231, 2599–2621. [Google Scholar] [CrossRef]
  10. Galis, Z.S.; Sukhova, G.K.; Lark, M.W.; Libby, P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Investig. 1994, 94, 2493–2503. [Google Scholar] [CrossRef]
  11. Tayebjee, M.H.; Lip, G.Y.; Tan, K.T.; Patel, J.V.; Hughes, E.A.; MacFadyen, R.J. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD-10 ligand levels in patients with stable coronary artery disease. Am. J. Cardiol. 2005, 96, 339–345. [Google Scholar] [CrossRef]
  12. Yasmin; Wallace, S.; McEniery, C.M.; Dakham, Z.; Pusalkar, P.; Maki-Petaja, K.; Ashby, M.J.; Cockcroft, J.R.; Wilkinson, I.B. Matrix metalloproteinase-9 (MMP-9), MMP-2 and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler. Tromb. Vasc. Biol. 2005, 25, 372–378. [Google Scholar] [CrossRef]
  13. Derosa, G.; D′Angelo, A.; Ciccarelli, L.; Piccinni, M.N.; Pricolo, F.; Salvadeo, S.; Montagna, L.; Gravina, A.; Ferrari, I.; Galli, S.; et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006, 13, 227–231. [Google Scholar] [CrossRef] [PubMed]
  14. Furenes, E.B.; Trøseid, M.; Solheim, S.; Hjerkinn, E.M.; Seljeflot, I.; Arnesen, H.; Weiss, T.W. Prediction of cardiovascular events by matrix metalloproteinase (MMP-9) in elderly men. Tromb. Haemost. 2010, 103, 679–681. [Google Scholar] [CrossRef]
  15. Wang, X.; Khalil, R.A. Matrix metalloproteinases, vascular remodeling, and vascular disease. Adv. Pharmacol. 2018, 81, 241–330. [Google Scholar] [PubMed]
  16. Zhang, B.; Henney, A.; Eriksson, P.; Hamsten, A.; Watkins, H.; Ye, S. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum. Genet. 1999, 105, 418–423. [Google Scholar]
  17. Blankenberg, S.; Rupprecht, H.J.; Poirier, O.; Bickel, C.; Smieja, M.; Hafner, G.; Meyer, J.; Cambien, F.; Tiret, L. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003, 107, 1579–1585. [Google Scholar] [CrossRef] [PubMed]
  18. Opstad, T.B.; Pettersen, A.-A.R.; Weiss, T.W.; Åkra, S.; Øvstebø, R.; Arnesen, H.; Seljeflot, I. Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease. Clin. Chim. Acta 2012, 413, 113–120. [Google Scholar] [CrossRef] [PubMed]
  19. Hassanzadeh-Makoui, R.; Razi, B.; Aslani, S.; Imani, D.; Tabaee, S.S. The association between Matrix Metallo-proteinases-9 (MMP-9) gene family polymorphisms and risk of Coronary Artery Disease (CAD): A systematic review and meta-analysis. BMC Cardiovasc. Disord. 2020, 20, 232. [Google Scholar] [CrossRef] [PubMed]
  20. Koh, Y.S.; Chang, K.; Kim, P.J.; Seung, K.B.; Baek, S.H.; Shin, W.S.; Lim, S.H.; Kim, J.H.; Choi, K.B. A close relationship between functional polymorphism in the promoter region of matrix metalloproteinase-9 and acute myocardial infarction. Int. J. Cardiol. 2008, 127, 430–432. [Google Scholar] [CrossRef]
  21. Rodríguez-Pérez, J.; Vargas-Alarcón, G.; Posadas-Sánchez, R.; Zagal-Jiménez, T.; Ortíz-Alarcón, R.; Valente-Acosta, B.; Tovilla-Zárate, C.; Nostroza-Hernández, C.; Pérez-Méndez, O.; Pérez-Hernández, N. rs3918242 MMP9 gene polymorphism is associated with myocardial infarction in Mexican patients. Genet. Mol. Res. 2016, 15, 15017776. [Google Scholar] [CrossRef]
  22. Gajewska, B.; Śliwińska-Mossoń, M. Association of MMP-2 and MMP-9 polymorphisms with diabetes and pathogenesis of diabetic complications. Int. J. Mol. Sci. 2022, 23, 10571. [Google Scholar] [CrossRef] [PubMed]
  23. Buraczynska, M.; Zakrocka, I. Arginase gene polymorphism increases risk of diabetic retinopathy in type 2 diabetes mellitus patients. J. Clin. Med. 2021, 10, 5407. [Google Scholar] [CrossRef] [PubMed]
  24. American Diabetes Association. Chapter 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes—2018. Diabetes Care 2018, 41, S13–S27. [Google Scholar] [CrossRef] [PubMed]
  25. Nie, S.W.; Wang, X.F.; Tang, Z.C. Correlations between MMP-2 / MMP-9 promoter polymorphisms and ischemic stroke. Int. J. Clin. Exp. Med. 2014, 7, 400–407. [Google Scholar]
  26. Gorący, I.; Grudniewicz, S.; Safranow, K.; Ciechanowicz, A.; Jakubiszyn, P.; Gorący, A.; Brykczyński, M. Genetic polymorphisms of MMP1, MMP9, COL1A1, and COL1A2 in polish patients with thoracic aortopathy. Dis. Markers 2020, 2020, 1–8. [Google Scholar] [CrossRef]
  27. Rawshani, A.; Rawshani, A.; Rawshani, A.; Franzén, S.; Sattar, N.; Eliasson, B.; Svensson, A.-M.; Zethelius, B.; Miftaraj, M.; McGuire, D.K.; et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2018, 379, 633–644. [Google Scholar] [CrossRef] [PubMed]
  28. Singh, K.; Agrawal, N.K.; Gupta, S.K.; Singh, K. A functional single nucleotide polymorphism -1562 C>T in the matrix metalloproteinase-9 promoter is associated with type 2 diabetes and diabetic foot ulcers. Int. J. Low. Extrem. Wounds 2013, 12, 199–204. [Google Scholar] [CrossRef] [PubMed]
  29. Zhang, Z.; Wu, X.; Cai, T.; Gao, W.; Zhou, X.; Zhao, J.; Yao, J.; Shang, H.; Dong, J.; Liao, L. Matrix metalloproteinase 9 gene promoter (rs3918242) mutation reduces risk of diabetic microvascular complications. Int. J. Environ. Res. Public Health 2015, 12, 8023–8033. [Google Scholar] [CrossRef]
  30. Buraczynska, K.; Kurzepa, J.; Ksiazek, A.; Buraczynska, M.; Rejdak, K. Matrix metalloproteinase-9 (MMP-9) gene poymorphism in stroke patients. Neuromol. Med. 2015, 17, 385–390. [Google Scholar] [CrossRef]
  31. Goracy, J.; Goracy, I.; Brykczyński, M.; Peregud-Pogorzelska, M.; Naruszewicz, M.; Ciechanowicz, A. [The C(-1562)T polymorphism in the promoter of the matrix metalloproteinase-9 (MMP-9) gene and coronary atherosclerosis]. Pol. Arch. Med. Wewn. 2003, 110, 1275–1281. [Google Scholar]
  32. Watson, C.; Spiers, J.P.; Waterstone, M.; Russell-Hallinan, A.; Gallagher, J.; McDonald, K.; Ryan, C.; Gilmer, J.; Ledwidge, M. Investigation of association of genetic variant rs3918242 of matrix metalloproteinase-9 with hypertension, myocardial infarction and progression of ventricular dysfunction in Irish Caucasian patients with diabetes: A report from the STOP-HF follow-up programme. BMC Cardiovasc. Disord. 2021, 21, 87. [Google Scholar] [CrossRef]
  33. Opstad, T.B.; Arnesen, H.; Pettersen, A.; Seljeflot, I. The MMP-9 -1562 C/T Polymorphism in the presence of metabolic syndrome increases the risk of clinical events in patients with coronary artery disease. PLoS ONE 2014, 9, e106816. [Google Scholar] [CrossRef] [PubMed]
  34. Boshev, M.; Stankovic, S.; Panov, S.; Josifovska, S.; Georgiev, A.; Poposka, L.; Pejkov, H. Association of the polymorphism rs3918242 of the matrix metalloproteinase-9 gene with coronary artery disease in a younger population. Contrib. Sec. Med. Sci. 2023, 44, 31–39. [Google Scholar] [CrossRef]
  35. Qin, L.; Qin, G.; Shi, X.; Wang, A.; Zuo, H. Association between matrix metalloproteinase-9 rs391824 polymorphism and development of coronary artery disease in a Chinese population. Genet. Mol. Res. 2016, 15, 2–8. [Google Scholar] [CrossRef] [PubMed]
  36. Kaplan, R.C.; Smith, N.L.; Zucker, S.; Heckbert, S.R.; Rice, K.; Psaty, B.M. Matrix metalloproteinase-3 (MMP-3) and MMP-9 genes and risk of myocardial infarction, ischemic stroke, and hemorrhagic stroke. Atherosclerosis 2008, 201, 130–137. [Google Scholar] [CrossRef]
  37. Mahmoodi, K.; Kamali, K.; Karami, E.; Soltanpour, M.S. Plasma concentration, genetic variation, and expression levels of matrix metalloproteinase 9 in Iranian patients with coronary artery disease. J. Res. Med. Sci. 2017, 22, 8. [Google Scholar] [PubMed]
  38. Basia, D.; Gupta, M.D.; Kunal, S.; Muheeb, G.; Girish, M.; Bansal, A.; Batra, V.; Yusuf, J.; Mukhopadhyay, S.; Tyagi, S.; et al. Matrix metalloproteinases and their gene polymorphism in young ST-segment elevation myocardial infarction. Indian Heart J. 2022, 74, 519–523. [Google Scholar] [CrossRef] [PubMed]
  39. Morgan, A.R.; Zhang, B.; Tapper, W.; Collins, A.; Ye, S. Haplotype analysis of MMP-9 gene in relation to coronary artery disese. J. Mol. Med. 2003, 81, 321–326. [Google Scholar] [CrossRef] [PubMed]
  40. Põllänen, P.J.; Karhunen, P.J.; Mikkelsson, I.; Laippala, P.; Perola, M.; Pentilla, A.; Mattila, K.M.; Koivula, T.; Lehtimäki, T. Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase-9 gene: An autopsy study. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 1446–1450. [Google Scholar] [CrossRef]
  41. Paulus, W.J.; Tschõppe, C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 2013, 62, 263–271. [Google Scholar] [CrossRef]
Table 1. Comparison of the clinical and laboratory characteristics of T2DM patients and healthy controls.
Table 1. Comparison of the clinical and laboratory characteristics of T2DM patients and healthy controls.
VariablesT2DM PatientsCVD+CVD−Healthy Controlsp Value *
N740522218400
Gender (male/female)392/348287/235105/113205/1950.082
Age (years)60.2 ± 9.463.6 ± 9.156.8 ± 9.657.5 ± 8.1<0.001
Age at diabetes diagnosis (years)43.2 ± 7.642.4 ± 7.144.0 ± 8.1NA0.007
Diabetes duration (years)15.0 ± 9.316.7 ± 8.313.3 ± 9.3NA<0.001
Total cholesterol (mmol/L)4.8 ± 1.24.9 ± 1.34.7 ± 1.04.0 ± 0.80.042
HDL cholesterol (mmol/L)1.21 ± 0.311.1 ± 0.21.3 ± 0.2ND<0.001
Triglyceride (mmol/L)2.1 ± 0.92.3 ± 0.81.9 ± 0.8ND<0.001
HbA1c (%)8.2 ± 2.58.3 ± 1.98.1 ± 3.1ND0.285
BMI (kg/m2)29.8 ± 8.830.4 ± 8.629.3. ± 9.027.1 ± 4.20.118
T2DM, type 2 diabetes mellitus; CVD+, those with cardiovascular disease; CVD−, those without cardiovascular disease; BMI, body mass index; HbA1c, glycated hemoglobin; NA, not applicable. ND, not determined. Data are reported as means ± SD or numbers and percentages (in parentheses). * p calculated for CVD+ vs. CVD−. In a comparison between the T2DM and control groups, statistically significant p-values were observed in age, total cholesterol and BMI (for all p < 0.001).
Table 2. Genotype and allele distribution of MMP-9 rs3918242 polymorphism in patients with T2DM and healthy controls.
Table 2. Genotype and allele distribution of MMP-9 rs3918242 polymorphism in patients with T2DM and healthy controls.
Genotypes MAFOR (95% CI) b
NCCCTTT T AlleleTT Genotype a
T2DM740377 (51)311 (42)52 (7)0.281.88 (1.51–2.34)3.77 (1.88–7.56)
p < 0.0001p = 0.0002
T2DM CVD+522214 (41)266 (51)42 (8)0.342.87 (2.14–3.85)3.19 (1.55–6.56)
p < 0.0001p = 0.0015
T2DM CVD−218163 (74)45 (21) 10 (5)0.15Ref. for T2DM CVD+
Controls400274 (68.5)116 (29)10 (2.5) 0.17Ref. for T2DM
T2DM, type 2 diabetes mellitus; T2DM CVD+, T2DM with cardiovascular disease; T2DM CVD−, T2DM without CVD. Genotype distribution is shown as numbers with percentages in parenthesis. a Calculated versus CC genotype. Hardy–Weinberg equilibrium: χ2 = 1.269, p = 0.259 for the T2DM group; χ2 = 0.305, p = 0.580 for the control group. b ORs adjusted for age, gender, lipid parameters and T2DM duration: T2DM vs. C: T allele 1.66 (1.31–2.43), p < 0.001; TT genotype 3.26 (1.72–8.31), p < 0.001; CVD+ vs. CVD−: T allele 3.14 (1.45–7.12), p < 0.001; TT genotype 2.96 (1.65–3.94), p < 0.001.
Table 3. Distribution of the MMP-9 rs3918242 polymorphism according to dominant and recessive genetic models.
Table 3. Distribution of the MMP-9 rs3918242 polymorphism according to dominant and recessive genetic models.
MMP-9 rs3918242T2DM CVD+T2DM CVD−OR (95% CI)p Value
C/T Genotypes(n = 522)(n = 218)
Dominant model
CC214 (41)163 (75)ref.
CT + TT308 (59)55 (25)4.26 (3.0–6.06) a<0.0001
Recessive model
CC + CT480 (92)208 (95) ref.
TT42 (8)10 (5)1.82 (0.89–3.69) b0.0976
MMP-9, matrix metalloproteinase 9 gene. T2DM, type 2 diabetes mellitus. Genotype distribution is shown as numbers with percentages in parenthesis. Odds ratio (OR) is related to the a CC homozygote and b CC + CT genotypes.
Table 4. CVD-associated parameters according to the carrier and non-carrier genotypes of MMP-9 rs3918242 polymorphism.
Table 4. CVD-associated parameters according to the carrier and non-carrier genotypes of MMP-9 rs3918242 polymorphism.
ParametersT2DM CVD+ (n = 522) T2DM CVD− (n = 218)
CCCT + TTp-ValueCCCT + TTp-Value
Age (years)63.4 ± 8.663.8 ± 9.60.62556.9 ± 9.156.7 ± 10.10.891
TC (mmol/L)4.9 ± 1.64.9 ± 1.01.0004.6 ± 1.34.8 ± 0.70.277
TG (mmol/L)2.3 ± 0.22.3 ± 1.31.0001.9 ± 1.01.8 ± 0.60.484
HDL (mmol/L)1.2 ± 0.11.0 ± 0.2<0.0011.3 ± 0.21.2 ± 0.3 0.005
SBP (mmHg)145 ± 20.2147 ± 18.50.242145 ± 17.6143 ± 19.30.477
DBP (mmHg)83 ± 11.282 ± 9.60.50985 ± 14.683 ± 10.30.348
DBP (mmHg)29.9 ± 6.830.9 ± 10.40.21728.8 ± 13.229.8 ± 4.80.583
T2DM, type 2 diabetes mellitus; T2DM CVD+, T2DM with cardiovascular disease. T2DM CVD−, T2DM without CVD. TC, total cholesterol. TG, triglyceride. HDL, high density lipoprotein. BMI, body mass index. SBP, systolic blood pressure. DBP, diastolic blood pressure. For CVD+ non-carriers (CC), n = 214; for carriers (CT + TT), n = 308. For CVD− non-carriers (CC), n = 163; for carriers (CT + TT), n = 55.
Table 5. The results of multivariate logistic regression analysis for independent risk factors for CVD.
Table 5. The results of multivariate logistic regression analysis for independent risk factors for CVD.
Included VariablesAdjusted Odds Ratio95% CIp Value
Age1.210.58–1.420.086
Gender1.620.85–1.930.072
T2DM duration1.470.76–2.080.047
Age of onset1.160.61–2.260.412
Hypertension1.840.73–3.940.073
Diabetic retinopathy2.531.62–4.230.028
Diabetic nephropathy1.970.65–2.740.058
Diabetic foot2.331.58–3.920.047
BMI1.270.84–1.460.267
T allele *2.481.86–4.62<0.001
T2DM, type 2 diabetes mellitus. * T allele of MMP-9 rs3918242 polymorphism. An unconditional model of multiple logistic regression analysis was used for the interaction between the MMP-9 gene polymorphism and other variables.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Buraczynska, M.; Wrzos, S.; Zaluska, W. MMP9 Gene Polymorphism (rs3918242) Increases the Risk of Cardiovascular Disease in Type 2 Diabetes Patients. J. Clin. Med. 2023, 12, 6990. https://doi.org/10.3390/jcm12226990

AMA Style

Buraczynska M, Wrzos S, Zaluska W. MMP9 Gene Polymorphism (rs3918242) Increases the Risk of Cardiovascular Disease in Type 2 Diabetes Patients. Journal of Clinical Medicine. 2023; 12(22):6990. https://doi.org/10.3390/jcm12226990

Chicago/Turabian Style

Buraczynska, Monika, Sylwia Wrzos, and Wojciech Zaluska. 2023. "MMP9 Gene Polymorphism (rs3918242) Increases the Risk of Cardiovascular Disease in Type 2 Diabetes Patients" Journal of Clinical Medicine 12, no. 22: 6990. https://doi.org/10.3390/jcm12226990

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop